%0 Journal Article %A S. Wesley Long %A Randall J. Olsen %A Paul A. Christensen %A Sishir Subedi %A Robert Olson %A James J. Davis %A Matthew Ojeda Saavedra %A Prasanti Yerramilli %A Layne Pruitt %A Kristina Reppond %A Madison N. Shyer %A Jessica Cambric %A Ilya J. Finkelstein %A Jimmy Gollihar %A James M. Musser %T Sequence Analysis of 20,453 SARS-CoV-2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern %D 2021 %R 10.1101/2021.02.26.21252227 %J medRxiv %P 2021.02.26.21252227 %X Since the beginning of the SARS-CoV-2 pandemic, there has been international concern about the emergence of virus variants with mutations that increase transmissibility, enhance escape from the human immune response, or otherwise alter biologically important phenotypes. In late 2020, several “variants of concern” emerged globally, including the UK variant (B.1.1.7), South Africa variant (B.1.351), Brazil variants (P.1 and P.2), and two related California “variants of interest” (B.1.429 and B.1.427). These variants are believed to have enhanced transmissibility capacity. For the South Africa and Brazil variants, there is evidence that mutations in spike protein permit it to escape from some vaccines and therapeutic monoclonal antibodies. Based on our extensive genome sequencing program involving 20,453 virus specimens from COVID-19 patients dating from March 2020, we report identification of all important SARS-CoV-2 variants among Houston Methodist Hospital patients residing in the greater metropolitan area. Although these variants are currently at relatively low frequency in the population, they are geographically widespread. Houston is the first city in the United States to have all variants documented by genome sequencing. As vaccine deployment accelerates worldwide, increased genomic surveillance of SARS-CoV-2 is essential to understanding the presence and frequency of consequential variants and their patterns and trajectory of dissemination. This information is critical for medical and public health efforts to effectively address and mitigate this global crisis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are indebted to Drs. Marc Boom and Dirk Sostman for their support, to many very generous Houston philanthropists for their tremendous support and to the Houston Methodist Academic Institute Infectious Diseases Fund that have made this ongoing project possible. James Davis and Robert Olson were funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Houston Methodist Research Institute Institutional Review Board (IRB1010-0199).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomes have been submitted to GISAID. https://www.gisaid.org/ %U https://www.medrxiv.org/content/medrxiv/early/2021/03/02/2021.02.26.21252227.full.pdf